What's particularly encouraging is the breadth of our execution across our portfolio. Auryon delivered another quarter of double-digit year-over-year growth. Our Mechanical Thrombectomy platforms continue to gain traction, both commercially and from a regulatory product development standpoint. NanoKnife is well positioned to capitalize on the prostate opportunity with the CPT code becoming effective a few days ago, and our Med Device business delivered solid results. Now let me walk you through each of our ...

Key Points The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty. However, the company's business appears to be improving. 10 stocks we like better than AngioDynamics › Shares of AngioDynamics (NASDAQ: ANGO) were sinking 13.1% as of 11:02 a.m. ET. The sell-off came after the medical technology company announced its third-quarter results before the market open. Those results were actually q ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Upgrades - UBS upgraded Brinker (EAT) to Buy from Neutral with a price target of $175, up from $144, citing the company's strong same-store sales momentum [2] - Raymond James upgraded Stryker (SYK) to Outperform from Market Perform with a price target of $418, indicating that the current valuation presents an attractive entry point [2] - BofA upgraded Allegiant Travel (ALGT) to Neutral from Underperform with a price target of $95, up from $55, noting that potential economic stimulus could benefit low-cost carriers and that Allegiant is maintaining flat capacity growth in 2026 [3] - Stephens upgraded Saia (SAIA) to Overweight from Equal Weight with a price target of $414, up from $308, believing that the bulk of new terminal noise is now resolved [4] - William Blair upgraded Medtronic (MDT) to Outperform from Market Perform, highlighting several new and ramping product launches this year [4] Downgrades - Wolfe Research downgraded Shopify (SHOP) to Peer Perform from Outperform, removing the previous price target of $185, due to elevated expectations and full valuation [5] - Freedom Capital downgraded Chevron (CVX) and Exxon Mobil (XOM) to Sell from Hold with price targets of $165 and $123, respectively, arguing that the current optimism in the U.S. oil and gas sector is unjustified [5] - UBS downgraded Lennar (LEN) to Neutral from Buy with a price target of $122, down from $137, suggesting that a return to 20%-plus gross margins may be delayed without a stronger industry recovery [5] - Wells Fargo downgraded D.R. Horton (DHI) to Equal Weight from Overweight with a price target of $155, down from $180, following recent analysis [5] - Baird downgraded Wells Fargo (WFC) to Underperform from Neutral, maintaining a price target of $90, citing limited upside for bank stocks in 2026 [5]

Core Insights - Hologic's Breast Health business has gained significant investor attention, particularly due to a proposed take-private transaction by Blackstone & TPG, which includes a fixed cash offer of $76 per share and a contingent value right (CVR) of up to $3 per share based on revenue metrics for fiscal years 2026 and 2027 [2][9] Business Segments - The Breast Health segment generates revenues from a diverse portfolio, including 3D digital mammography systems and biopsy solutions, with the addition of Endomagnetics in fiscal 2024 contributing $54.9 million in product revenues for fiscal 2025 [3][9] - The Breast Health service business provides recurring revenues through service contracts for the global installed base of gantries, helping to mitigate volatility in capital sales [4][9] Innovation and Technology - Hologic has focused on innovation, introducing FDA-approved technologies such as 3DQuorum Imaging Technology and the next-generation Genius AI Detection PRO software, which reduces radiologists' reading time [5] - The company is advancing contrast-enhanced mammography with I-View 2.0 software and plans to commercially introduce the Envision Mammography Platform, featuring the first FDA-approved mammography focusing technology [5] Competitor Landscape - GE HealthCare has secured a contract to supply over 300 CT scanners in Indonesia, aiming to enhance healthcare access for over 280 million people [6] - Quest Diagnostics and Corewell Health have established a joint venture to expand laboratory services in Michigan, with Quest holding a 51% equity stake [7] Stock Performance and Valuation - Hologic's stock has increased by 11% over the past three months, outperforming the industry growth of 3.7% [8] - The company is trading at a forward five-year price-to-sales (P/S) ratio of 3.83, which is lower than the industry average of 4.11 [10]

Financial Data and Key Metrics Changes - Revenue increased by 8.8% to $79.4 million, with Med Tech up 13% and Med Device up 5.6% [5][14] - Adjusted EBITDA nearly doubled year-over-year, reaching $5.9 million compared to $3.1 million in the previous year [22] - Gross margin improved to 56.4%, a 170 basis point increase from the previous year [18][19] - Adjusted net loss reduced to $0.1 million, or an adjusted loss per share of $0.001, compared to an adjusted net loss of $1.7 million, or an adjusted loss per share of $0.04 in the prior year [22] Business Line Data and Key Metrics Changes - Med Tech revenue was $35.7 million, a 13% increase, contributing 45% of total revenue compared to 43% a year ago [14] - Auryon platform revenue grew 18.6% to $16.3 million, marking 18 consecutive quarters of double-digit growth [14][15] - Mechanical thrombectomy revenue increased by 3.9% to $11 million, with AlphaVac revenue up 40.2% to $3.5 million, while AngioVac revenue decreased by 7.5% to $7.5 million [15][16] - NanoKnife revenue rose 22.2% to $7.3 million, driven by increased demand for prostate cancer procedures [17] Market Data and Key Metrics Changes - International sales for Auryon are expected to grow following CE mark approval, with ongoing efforts to increase market penetration [6][58] - The company is targeting expansion into coronary applications, although significant R&D spending is not anticipated in the current fiscal year [59] Company Strategy and Development Direction - The company is focused on increasing the percentage of revenue from higher growth, higher margin Med Tech segments [14] - Strategic initiatives include expanding the addressable market for Auryon and enhancing the mechanical thrombectomy portfolio through regulatory approvals [6][8] - The company aims to balance current operational efficiency with investments for long-term growth [11][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to generate cash flow and maintain profitability while investing in growth initiatives [11][23] - The company raised its full-year guidance for revenue and adjusted EBITDA based on strong second-quarter performance [24][25] - Management highlighted the importance of regulatory milestones in enhancing competitive positioning and expanding clinical applications [8][9] Other Important Information - The company announced a leadership transition, with the current CEO planning to retire after a decade, and a search for a new CEO is underway [28][29] - A favorable court ruling regarding patent litigation with C.R. Bard eliminates a potential $3 million payment, concluding a long-standing legal matter [26] Q&A Session Summary Question: Comments on gross margin expectations - Management noted strong gross margin performance driven by positive pricing and a favorable product mix, but anticipated structural underabsorption in the second half due to manufacturing transitions [34][36] Question: Insights on mechanical thrombectomy performance - Management expressed optimism about AlphaVac's growth and acknowledged AngioVac's challenging year-over-year comparison, but remained confident in its long-term potential [39][40] Question: Update on prostate procedures and CPT code changes - Management indicated that it is too early to assess the impact of the new CPT code on insurer responses but sees it as a potential catalyst for growth [49] Question: Adjusted EBITDA expectations for the third quarter - Management expects positive adjusted EBITDA in the third quarter, though it may not be as robust as the first half due to planned investments [53]

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) ("STAAR†), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, announced that based on preliminary estimates by STAAR's proxy solicitor, STAAR did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held today. STAAR intends to terminate its merger agreement with Alcon. No termination fee wil ...

Core Insights - CVRx, Inc. has transitioned to Category I Current Procedural Terminology (CPT) codes for its Barostim device, effective January 1, 2026, replacing the previous Category III codes, which is expected to enhance adoption, coverage, and reimbursement for the therapy [1][2][3] Company Overview - CVRx, Inc. is a commercial-stage medical device company that specializes in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases [3] - The Barostim device is the first FDA-approved medical technology that utilizes neuromodulation to alleviate symptoms in heart failure patients [3] - Barostim functions by delivering electrical pulses to baroreceptors in the carotid artery, aiming to restore balance to the autonomic nervous system and reduce heart failure symptoms [3] Regulatory and Market Impact - The new Category I CPT codes are anticipated to provide more predictable and consistent reimbursement for healthcare professionals and patients using Barostim therapy [3] - The Barostim device has received FDA Breakthrough Device designation and is approved for use in heart failure patients in the U.S., as well as being compliant with EU Medical Device Regulation and holding CE Mark approval for heart failure and resistant hypertension in the European Economic Area [3]

Core Insights - SS Innovations International, Inc. has developed five new 5-millimeter surgical instruments aimed at enhancing robotic surgery across various specialties, including pediatric, cardiac, and head and neck surgery [1][2][3] Company Developments - The new instruments include a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps, designed for use in critical surgical procedures [2] - The cumulative installed base of the SSi Mantra surgical robotic system reached 168 systems as of December 31, 2025, with 12 systems deployed in nine countries outside of India [3] - Over 7,800 surgical procedures have been performed using the SSi Mantra, including more than 120 telesurgeries and over 400 cardiac procedures [3] Market Opportunity - Approximately 1.7 billion children and adolescents globally lack access to essential surgical care, with over 390 million children under five in lower- and middle-income countries not receiving timely surgical interventions [3] - The development of smaller surgical instruments aims to make robotic surgery more accessible to pediatric patients, addressing a significant gap in the current healthcare landscape [3] Product Features - The SSi Mantra surgical robotic system is characterized by its user-friendly, modular design, featuring 3 to 5 robotic arms, a 3D 4K monitor, and advanced imaging capabilities [6] - The system has been clinically validated in India for over 100 different types of surgical procedures, showcasing its versatility and effectiveness [6] Future Focus - The company plans to continue developing differentiated surgical robotic technologies to benefit a larger segment of patients globally, particularly in underserved populations [3]

Core Insights - Hyperfine has announced the first analysis indicating that its AI-powered Swoop® portable MRI system is effective in reducing hospital costs and enhancing economic outcomes in acute care settings [1] Company Summary - Hyperfine's Swoop® portable MRI system utilizes artificial intelligence to improve the efficiency and cost-effectiveness of MRI imaging in hospitals [1]